Bendamustine treatment before apheresis is known to reduce survival in large B-cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T-cell therapy. Bendamustine has been shown to ...

The bendamustine molecule is composed of 3 structural elements: a mechlorethamine (nitrogen mustard) group, a benzimidazole ring, and a butyric acid side chain (Figure 1). The mechlorethamine ...

Am J Health Syst Pharm. 2010;67(9):713-723. To date, no clinical studies have been conducted regarding potential drug interactions. However, in vitro data indicate that the formation of the two known ...

Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group A total of 245 courses (median, four ...

Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic ...

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial The study included CAR T-cell ...

The Appraisal Committee considered evidence submitted by the manufacturer of bendamustine and a review of this submission by the Evidence Review Group (ERG). One trial was identified by the ...

On Friday, Cephalon Inc. announced that the FDA approved bendamustine hydrochloride injection (Treanda) for use in patients with relapsed indolent non-Hodgkin’s lymphoma. The drug is approved for ...

“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an ...

The appraisal committee considered evidence submitted by Roche, a review of this submission by the evidence review group (ERG), and the technical report developed through engagement with stakeholders.